10-YEAR CARDIOVASCULAR RISK REDUCTION, EFFICACY AND SAFETY OF ALIROCUMAB AND EVOLOCUMAB, IN ADDITION TO MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY: POST-COMMERCIALIZATION STUDY

2017 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []